315 related articles for article (PubMed ID: 14703954)
1. Cyclosporin C2hour monitoring after renal transplantation.
Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Glander P; Böhler T; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):477-81. PubMed ID: 14703954
[TBL] [Abstract][Full Text] [Related]
2. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression.
Einecke G; Mai I; Fritsche L; Slowinski T; Waiser J; Neumayer HH; Budde K
Nephrol Dial Transplant; 2004 Jan; 19(1):215-22. PubMed ID: 14671060
[TBL] [Abstract][Full Text] [Related]
3. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.
Internation Neoral Renal Transplantation Study Group
Am J Transplant; 2002 Feb; 2(2):157-66. PubMed ID: 12099518
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
Rodríguez E; Delucchi MA; Cano F; Valdebenito S; Castillo MC; Villegas R
Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
[TBL] [Abstract][Full Text] [Related]
5. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
7. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
Büchler M; Chadban S; Cole E; Midtvedt K; Thervet E; Prestele H; Keown P
Nephrol Dial Transplant; 2006 Jan; 21(1):197-202. PubMed ID: 16204301
[TBL] [Abstract][Full Text] [Related]
8. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
9. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function.
Waiser J; Slowinski T; Brinker-Paschke A; Budde K; Schreiber M; Böhler T; Hauser I; Neumayer HH
Nephrol Dial Transplant; 2002 Jul; 17(7):1310-7. PubMed ID: 12105257
[TBL] [Abstract][Full Text] [Related]
10. Limitations of C2 monitoring in renal transplant recipients.
Einecke G; Schütz M; Mai I; Fritsche L; Giessing M; Glander P; Neumayer HH; Budde K
Nephrol Dial Transplant; 2005 Jul; 20(7):1463-70. PubMed ID: 15840681
[TBL] [Abstract][Full Text] [Related]
11. Improving the therapeutic monitoring of cyclosporin A.
Warrens AN; Waters JB; Salama AD; Lechler RI
Clin Transplant; 1999 Apr; 13(2):193-200. PubMed ID: 10202617
[TBL] [Abstract][Full Text] [Related]
12. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients.
Belitsky P; Dunn S; Johnston A; Levy G
Clin Pharmacokinet; 2000 Aug; 39(2):117-25. PubMed ID: 10976658
[TBL] [Abstract][Full Text] [Related]
13. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month.
Morris RG; Russ GR; Cervelli MJ; Juneja R; McDonald SP; Mathew TH
Ther Drug Monit; 2002 Aug; 24(4):479-86. PubMed ID: 12142630
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients.
Solari SG; Goldberg LR; DeNofrio D; Shaw LM
Ther Drug Monit; 2005 Aug; 27(4):417-21. PubMed ID: 16044096
[TBL] [Abstract][Full Text] [Related]
15. Experience with therapeutic drug monitoring of cyclosporine.
Abendroth D
Transplant Proc; 2004 Mar; 36(2 Suppl):426S-429S. PubMed ID: 15041379
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
17. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Hübler M; Abd El Rahman MY; Miera O; Ewert P; Weng Y; Wei H; Krüdewagen B; Hetzer R; Berger F
J Heart Lung Transplant; 2006 Jun; 25(6):619-25. PubMed ID: 16730566
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection.
Weber LT; Armstrong VW; Shipkova M; Feneberg R; Wiesel M; Mehls O; Zimmerhackl LB; Oellerich M; Tönshoff B;
Ther Drug Monit; 2004 Aug; 26(4):415-24. PubMed ID: 15257072
[TBL] [Abstract][Full Text] [Related]
19. Two-hour post-dose cyclosporine levels in renal transplantation in Argentina: a cost-effective strategy for reducing acute rejection.
Balshaw R; Machnicki G; Carreño CA; Toselli L; Otero A; Keown PA
Transplant Proc; 2005 Mar; 37(2):871-4. PubMed ID: 15848560
[TBL] [Abstract][Full Text] [Related]
20. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
Bunnag S; Vareesangthip K; Ong-ajyooth L
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
